Trastuzumab is indicated for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Breast Cancer
Latest News
Advertisement
CME Content
Advertisement
With this approval, atezolizumab plus nab-paclitaxel is the first cancer immunotherapy regimen to be approved for breast cancer.
Atezolizumab (Tecentriq) plus chemotherapy is approved under the FDA’s Accelerated Approval Program, which allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.
Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.
Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Top news of the day from across the health care landscape.
The new class of smart drugs has the ability to bring the toxic payload directly to the cancer cells.
This study demonstrates the significance and efficacy of breast cancer screenings for prevention and early intervention.
Translational study of breast cancer therapy sought to ‘take research from bench to bedside.’
Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.
Researchers have identified a link between CXCR4 expression, fibrosis, and immunosuppression in patients with metastatic breast cancer.
Top news of the day across the health care landscape.
Researchers aimed to better understand the different ways that breast cancer avoids immune system detection.
Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.
Hot flashes are a huge problem across the general population, but even more so in breast cancer survivors.
The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing.
Top news of the day from across the health care landscape
Former New York Giants running back Tiki Barber discusses his mother's fight against breast cancer and his advocacy for cancer awareness.
Prescriptions for hormonal therapy medications increased in states that expanded Medicaid, according to a recent analysis.
Top news of the day from across the health care landscape.
Study highlights mechanism of endocrine resistance in estrogen receptor-positive breast cancers and potential therapeutic targets.
Top news of the week from Specialty Pharmacy Times.
Older women undergoing chemotherapy for breast cancer have a higher risk of experiencing a decline in their ability to function physically.
The effect of chemotherapy on functional status can be critical for older adults, as declining function can inhibit the ability to live independently and perform daily activities.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen–Naproxen Combination for 12-Hour Pain Relief
2
FDA Approves Furosemide Autoinjector for Treatment of Edema in CKD or Heart Failure
3
What Real-World Data Show About Moving Patients From Humira to Biosimilars
4
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
5